AMEX · Analyst Forecast

Cybin Inc. (CYBN) Analyst Forecast

$8.28 AMEX: CYBN Market Cap $413.02M

Revenue and earnings estimates published by analysts covering Cybin Inc. (CYBN), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Cybin Inc., the average estimate for 2030 earnings per share is $3.31; 5 analysts contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$0$0$03
2026$0$0$03
2027$12.51T$12.51T$12.51T5
2028$22.45T$22.45T$22.45T4
2029$0$0$01
2030$0$0$01

Earnings per share forecast

YearLowAverageHighAnalysts
2025$-6.36$-5.02$-3.683
2026$-4.61$-4.38$-4.133
2027$-3.40$-3.40$-3.405
2028$-4.21$-3.44$-2.454
2029$-0.23$-0.23$-0.231
2030$3.31$3.31$3.311

Cybin Inc. (CYBN) forecast — frequently asked questions

What are analysts forecasting for Cybin Inc.'s earnings?

The average analyst estimate for Cybin Inc. (CYBN) earnings per share in 2030 is 3.31, with individual estimates between 3.31 and 3.31.

How much revenue is Cybin Inc. expected to make?

Analysts forecast Cybin Inc. (CYBN) revenue of $0 in 2030, based on 1 published estimates.

How many analysts cover CYBN?

5 analysts contribute estimates for Cybin Inc. (CYBN). Thin coverage makes an average less reliable.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.